LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
LivaNova PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$78.14+0.56 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $4.40B
- P/E (TTM)
- 23.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
59M of 55M shares
Institutional holders
303
54 new, 36 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $1.05M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,922,335 | 12.70% | 13G (passive) amendment | Jun 30, 2025 |
| Primecap Management Co/Ca/ | 4,224,852 | 7.74% | 13G (passive) amendment | Dec 31, 2025 |
| Millennium Group Management LLC | 3,484,082 | 6.40% | 13G (passive) amendment | Dec 31, 2025 |
| Abigail P. Johnson | 3,210,395 | 5.80% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LIVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,565,342 | 13.73% | $622.10M | +426,434 | 0.01% |
| Primecap Management Co/Ca/ | 4,168,377 | 7.57% | $342.77M | −38,675 | 0.20% |
| FMR LLC | 3,147,068 | 5.71% | $258.78M | +480,394 | 0.01% |
| Hood River Capital Management LLC | 2,565,477 | 4.66% | $210.96M | +1,928,937 | 1.53% |
| Aqr Capital Management LLC | 2,356,191 | 4.28% | $191.02M | −138,181 | 0.07% |
| Invesco Ltd. | 2,237,319 | 4.06% | $183.97M | +613,110 | 0.01% |
| Artisan Partners Limited Partnership | 2,224,763 | 4.04% | $182.94M | +101,947 | 0.29% |
| State Street Corp | 2,165,863 | 3.93% | $178.10M | +93,184 | 0.01% |
| American Century Companies Inc | 2,013,774 | 3.66% | $165.59M | +218,839 | 0.07% |
| Dimensional Fund Advisors LP | 1,845,285 | 3.35% | $151.74M | +19,037 | 0.03% |
| Geode Capital Management, LLC | 1,755,648 | 3.19% | $144.39M | +257,877 | 0.01% |
| Wellington Management Group Llp | 1,739,167 | 3.16% | $143.01M | −151,482 | 0.02% |
| Congress Asset Management Co /Ma | 1,502,244 | 2.73% | $123.53M | +227,424 | 0.76% |
| Vanguard Portfolio Management LLC | 1,414,832 | 2.57% | $116.34M | +70,543 | 0.01% |
| Greenhouse Funds LLLP | 924,128 | 1.68% | $75.99M | +155,833 | 3.88% |
| Victory Capital Management Inc | 851,820 | 1.55% | $70.05M | +18,552 | 0.04% |
| Emerald Advisers, LLC | 787,101 | 1.43% | $64.72M | +116,894 | 1.52% |
| Nuveen, LLC | 727,968 | 1.32% | $59.86M | −192,375 | 0.01% |
| Northern Trust Corp | 697,776 | 1.27% | $57.38M | +31,466 | 0.01% |
| Goldman Sachs Group Inc | 695,721 | 1.26% | $57.21M | −103,230 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 303 | 59M | 100.0% | 54 / 120 | 84 / 36 | 7M | 6M |
| Q1 2026 | 292 | 59M | 100.0% | 55 / 118 | 82 / 31 | 13M | 7M |
| Q4 2025 | 273 | 55M | 99.6% | 43 / 104 | 89 / 34 | 6M | 7M |
| Q3 2025 | 271 | 55M | 100.0% | 48 / 88 | 109 / 26 | 7M | 7M |
| Q2 2025 | 252 | 55M | 100.0% | 41 / 104 | 82 / 36 | 9M | 8M |
| Q1 2025 | 249 | 54M | 97.8% | 35 / 100 | 88 / 40 | 8M | 8M |
| Q4 2024 | 256 | 54M | 98.8% | 48 / 109 | 69 / 34 | 8M | 6M |
| Q3 2024 | 243 | 52M | 94.9% | 46 / 83 | 90 / 30 | 13M | 9M |
| Q2 2024 | 230 | 55M | 100.0% | 35 / 87 | 80 / 35 | 8M | 10M |
| Q1 2024 | 231 | 57M | 100.0% | 47 / 82 | 72 / 29 | 8M | 5M |
| Q4 2023 | 215 | 55M | 100.0% | 34 / 72 | 83 / 28 | 5M | 3M |
| Q3 2023 | 211 | 54M | 97.2% | 30 / 68 | 89 / 18 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LIVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Capital Opportunity Fund | 1,902,700 | 3.45% | $156.46M | 0.48% | Jun 30, 2026 |
| Invesco Small Cap Value Fund | 1,679,556 | 3.05% | $134.60M | 1.21% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 1,616,502 | 2.93% | $119.30M | 0.44% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 629,753 | 1.14% | $51.78M | 0.05% | Jun 30, 2026 |
| Vanguard Primecap Core Fund | 582,430 | 1.06% | $47.89M | 0.27% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 447,300 | 0.81% | $36.78M | 2.28% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 373,124 | 0.68% | $29.90M | 0.55% | Jul 31, 2026 |
| Touchstone Strategic Trust-Touchstone Small Company Fund | 361,636 | 0.66% | $29.74M | 1.73% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 336,011 | 0.61% | $27.63M | 0.23% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 280,087 | 0.51% | $20.67M | 0.12% | May 31, 2026 |
| iShares U.S. Medical Devices ETF | 257,248 | 0.47% | $21.15M | 0.70% | Jun 30, 2026 |
| Dimensional U.S. Targeted Value ETF | 206,913 | 0.38% | $16.58M | 0.11% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 202,420 | 0.37% | $16.22M | 0.40% | Jul 31, 2026 |
| SmallCap Growth Fund I | 198,650 | 0.36% | $15.92M | 0.64% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 183,472 | 0.33% | $14.70M | 0.10% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vladimir Makatsaria | Chief Executive Officer, Director | 25,326 | 0.05% | Apr 1, 2026 |
| Anne M. Liddy | Chief Legal Officer | – | – | Sep 16, 2026 |
| Ahmet Tezel | Chief Innovation Officer | 18,782 | 0.03% | Aug 13, 2026 |
| Stefano Folli | President, Cardiopulmonary | – | – | Aug 5, 2026 |
| Stephanie Bolton | President, Global Epilepsy | 30,566 | 0.06% | Apr 1, 2026 |
| Alex Shvartsburg | Chief Financial Officer | 44,647 | 0.08% | Apr 1, 2026 |
| Franco Poletti | President, Cardiopulmonary | 12,344 | 0.02% | Apr 1, 2026 |
| Natalia Kozmina | Chief Human Resources Officer | 5,015 | 0.01% | Apr 1, 2026 |
| Michael Damon Hutchinson | SVP, CLO and Company Secretary | 7,920 | 0.01% | Dec 17, 2025 |
| Francesco Bianchi | Director | 4,434 | 0.01% | Sep 14, 2026 |
| Brooke Story | Director | 7,488 | 0.01% | Sep 8, 2026 |
| Jette Nygaard-Andersen | Director | 0 | – | Jun 17, 2026 |
| Susan M. Podlogar | Director | 6,128 | 0.01% | Jun 17, 2026 |
| William A. Kozy | Director | 38,248 | 0.07% | Jun 17, 2026 |
| Peter M. Wilver | Director | 10,780 | 0.02% | Jun 17, 2026 |
| Todd C. Schermerhorn | Director | 13,105 | 0.02% | Jun 17, 2026 |
| Seng Stacy Enxing | Director | 15,793 | 0.03% | Jun 17, 2026 |
| Donald Zurbay | Director | 2,560 | 0.00% | Jun 17, 2026 |
| James Christopher Barry | Director | 8,404 | 0.02% | Jun 17, 2026 |
| Sharon O'Kane | Director | 12,910 | 0.02% | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Francesco Bianchi Director | Sep 10, 2026 | Sale | −3,500 | $78.01 | $273.04K | 4,434 |
| Brooke Story Director | Sep 4, 2026 | Sale | −2,300 | $81.42 | $187.27K | 7,488 |
| Francesco Bianchi Director | Aug 31, 2026 | Sale | −1,650 | $79.72 | $131.54K | 7,934 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Option exercise | +12,692 | $52.68 | $668.61K | 18,782 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Sale | −2,675 | $77.74 | $207.95K | 6,090 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Returned to company | −8,589 | $77.86 | $668.74K | 10,193 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Tax withholding | −1,428 | $77.86 | $111.18K | 8,765 |
| William A. Kozy Director | Jun 15, 2026 | Option exercise | +5,681 | – | – | 38,248 |
| William A. Kozy Director | Jun 15, 2026 | Tax withholding | −682 | $79.70 | $54.36K | 37,566 |
| Peter M. Wilver Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 10,780 |
| Peter M. Wilver Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 10,294 |
| Todd C. Schermerhorn Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 13,105 |
| Todd C. Schermerhorn Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 12,619 |
| James Christopher Barry Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 8,404 |
| James Christopher Barry Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 7,918 |
| Francesco Bianchi Director | Jun 15, 2026 | Sale | −1,200 | $80.19 | $96.23K | 9,584 |
| Francesco Bianchi Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 11,270 |
| Francesco Bianchi Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 10,784 |
| Susan M. Podlogar Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 6,128 |
| Susan M. Podlogar Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 5,642 |
| Brooke Story Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 10,274 |
| Brooke Story Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 9,788 |
| Seng Stacy Enxing Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 15,793 |
| Seng Stacy Enxing Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 15,307 |
| Ahmet Tezel Chief Innovation Officer | Jun 15, 2026 | Tax withholding | −1,032 | $79.70 | $82.25K | 6,090 |
| Ahmet Tezel Chief Innovation Officer | Jun 15, 2026 | Option exercise | +2,965 | – | – | 7,122 |
| Donald Zurbay Director | Jun 15, 2026 | Option exercise | +2,560 | – | – | 2,560 |
| Donald Zurbay Director | Jun 15, 2026 | Tax withholding | −308 | $79.70 | $24.55K | 2,252 |
| Francesco Bianchi Director | May 26, 2026 | Sale | −1,800 | $75.75 | $136.35K | 7,228 |
| Natalia Kozmina Chief Human Resources Officer | Mar 30, 2026 | Tax withholding | −1,374 | $61.27 | $84.18K | 5,015 |
| Natalia Kozmina Chief Human Resources Officer | Mar 30, 2026 | Option exercise | +6,389 | – | – | 6,389 |
| Alex Shvartsburg Chief Financial Officer | Mar 30, 2026 | Tax withholding | −12,868 | $61.27 | $788.42K | 44,647 |
| Alex Shvartsburg Chief Financial Officer | Mar 30, 2026 | Option exercise | +30,835 | – | – | 57,515 |
| Vladimir Makatsaria Chief Executive Officer, Director | Mar 30, 2026 | Option exercise | +21,042 | – | – | 25,326 |
| Vladimir Makatsaria Chief Executive Officer, Director | Mar 30, 2026 | Tax withholding | −11,159 | $61.27 | $683.71K | 14,167 |
| Franco Poletti President, Cardiopulmonary | Mar 30, 2026 | Option exercise | +3,184 | – | – | 12,125 |
| Franco Poletti President, Cardiopulmonary | Mar 30, 2026 | Tax withholding | −1,370 | $61.27 | $83.94K | 10,755 |
| Stephanie Bolton President, Global Epilepsy | Mar 30, 2026 | Option exercise | +17,815 | – | – | 30,566 |
| Stephanie Bolton President, Global Epilepsy | Mar 30, 2026 | Tax withholding | −8,377 | $61.27 | $513.26K | 22,189 |
| Ahmet Tezel Chief Innovation Officer | Mar 30, 2026 | Option exercise | +3,408 | – | – | 5,343 |
| Ahmet Tezel Chief Innovation Officer | Mar 30, 2026 | Tax withholding | −1,186 | $61.27 | $72.67K | 4,157 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Tax withholding | −1,980 | $62.26 | $123.27K | 9,010 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Tax withholding | −69 | $62.26 | $4.30K | 8,941 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Option exercise | +2,140 | $57.60 | $123.26K | 10,990 |
| Franco Poletti President, Cardiopulmonary | Dec 15, 2025 | Option exercise | +967 | – | – | 9,266 |
| Franco Poletti President, Cardiopulmonary | Dec 15, 2025 | Tax withholding | −416 | $63.06 | $26.23K | 8,850 |
| Michael Damon Hutchinson SVP, CLO and Company Secretary | Dec 15, 2025 | Option exercise | +2,254 | – | – | 7,920 |
| Michael Damon Hutchinson SVP, CLO and Company Secretary | Dec 15, 2025 | Tax withholding | −1,122 | $63.06 | $70.75K | 6,798 |
| Susan M. Podlogar Director | Dec 15, 2025 | Tax withholding | −269 | $63.06 | $16.96K | 2,086 |
| Susan M. Podlogar Director | Dec 15, 2025 | Option exercise | +2,355 | – | – | 2,355 |
| Brooke Story Director | Nov 18, 2025 | Sale | −250 | $53.94 | $13.49K | 6,232 |
| Franco Poletti President, Cardiopulmonary | Sep 15, 2025 | Option exercise | +643 | – | – | 8,576 |
| Franco Poletti President, Cardiopulmonary | Sep 15, 2025 | Tax withholding | −277 | $55.43 | $15.35K | 8,299 |
| Francesco Bianchi Director | Aug 25, 2025 | Sale | −1,500 | $56.50 | $84.75K | 9,028 |
| Peter M. Wilver Director | Jun 15, 2025 | Tax withholding | −410 | $45.76 | $18.76K | 6,738 |
| Peter M. Wilver Director | Jun 15, 2025 | Option exercise | +3,416 | – | – | 7,148 |
| Francesco Bianchi Director | Jun 15, 2025 | Option exercise | +3,416 | – | – | 10,938 |
| Francesco Bianchi Director | Jun 15, 2025 | Tax withholding | −410 | $45.76 | $18.76K | 10,528 |
| William A. Kozy Director | Jun 15, 2025 | Tax withholding | −581 | $45.76 | $26.59K | 32,567 |
| William A. Kozy Director | Jun 15, 2025 | Option exercise | +4,840 | – | – | 33,148 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Francesco Bianchi Officer | Sep 10, 2026 | 3,500 | $273.03K | Sep 10, 2026 | Vesting of restricted stock unit award |
| Brooke Story Officer | Sep 4, 2026 | 2,300 | $187.27K | Sep 4, 2026 | Vesting of restricted stock unit award |
| Franco Poletti Officer | Sep 2, 2026 | 10,755 | $882.89K | Sep 2, 2026 | Vesting of restricted stock unit awards |
| Francesco Bianchi Officer | Aug 31, 2026 | 1,650 | $131.54K | Aug 31, 2026 | Vesting of restricted stock unit award |
| Ahmet Tezel Officer | Aug 11, 2026 | 2,675 | $209.94K | Aug 11, 2026 | Exercise of employee stock appreciation rights |
| Francesco Bianchi Officer | Jun 15, 2026 | 1,200 | $96.23K | Jun 15, 2026 | Vesting of restricted stock unit award |
| Francesco Bianchi Officer | May 26, 2026 | 1,800 | $136.35K | May 26, 2026 | Vesting of restricted stock unit award |
| Brooke Story Director | Nov 18, 2025 | 250 | $13.49K | Nov 18, 2025 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Aug 25, 2025 | 1,500 | $84.75K | Aug 25, 2025 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Dec 11, 2024 | 1,250 | $63.74K | Dec 11, 2024 | Vesting of restricted stock unit award |
| Trui Hebbelinck Officer | Dec 10, 2024 | 6,000 | $301.62K | Dec 10, 2024 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Sep 11, 2024 | 1,500 | $69.87K | Sep 11, 2024 | Vesting of restricted stock unit award |
| Daniel Jeffrey Moore Director | Jun 3, 2024 | 56,623 | $3.40M | Jun 3, 2024 | Exercise of employee stock options |
| Damien McDonald Officer | Jun 23, 2023 | 20,000 | $990.00K | Jun 23, 2023 | Vesting of restricted stock unit award |
| Damien McDonald Officer | Jun 20, 2023 | 8,847 | $452.32K | Jun 20, 2023 | Exercise of employee stock appreciation rights |